Luc Grégoire
President and Chief Executive Officer
Mr. Grégoire is a seasoned strategic executive and board member, with extensive experience in various industries including software, digital media and entertainment, and health sciences. He began his career at Arthur Andersen where he was an international tax partner. He then held various finance and strategic roles at Merck & Co, including CFO of Merck Frosst Canada, progressing to global roles in Merck’s US corporate headquarters.
Mr. Grégoire was most recently the CFO of InforMed Data Services Inc (d/b/a One Drop) (“InfoMed”), a growth stage health tech and medical devices company for diabetes management, backed by Bayer. Effective October 1, 2022, Mr. Gégoire retired from his position as CFO of InfoMed. Prior to InfoMed, Mr. Grégoire was the CFO for DHI Group, Inc. (DHX, NYSE) from November 2016 to January 2021 and AvePoint Inc. (AVPT, NYSE) from October 2014 to October 2016. Prior to AvePoint Inc., Mr. Grégoire held different executive Finance positions at these global public companies: Take Two Interactive Inc, The McGraw Hill Companies and Standard Motor Products Inc.
His career spans over 40 years of experience in accounting, taxation, treasury, financial planning, auditing, merger and acquisition, capital markets and investor relations, corporate governance, as well as international operations and general business management. Through his career, he developed effective and strategic leadership skills and an extensive public and private capital markets outreach strategies, including ongoing interaction with investors, buy and sell-side analysts, capital raises and shareholder activism. Since 2016, Mr. Gregoire has also served on the board of directors of Werber Management Inc., a New York-based residential real estate company. Mr. Grégoire is a CPA-Chartered Accountant, as well as a graduate of Concordia University – B. Comm (1981) and McGill University – Grad Dip. Accountancy (1984).
André P. Boulet, Ph.D.
Chief Operating Officer
Chief Scientific Officer
Dr André Boulet has a vast experience in drug development, regulatory affairs, market access, financing and restructuration in the pharmaceutical and biotech fields. A seasoned entrepreneur, he stands out by combining his strengths in applied science, business and finance.
Within Devonian Health Group, he has raised more than $50M in private/public equity, completed phase 1 and phase 2 ulcerative colitis and Atopic Dermatitis clinical programs for the company`s flagship product Thykamine™ as well as a complete line of patented anti-aging products.
Prior to this endeavour, he was a managing partner of SIPAR’s biotech unit, a $400M private investment firm. Prior to SIPAR, Dr Boulet was partner at BioCapital III LP (« BioCapital ») (1996-2002), a Canadian biotech venture capital company.
Throughout his career, Dr Boulet acquired an international expertise in drug development, regulatory affairs and health economics within Hoechst Marion Roussel, Marion Merrell Dow Canada and Laboratoires Nordic (now Sanofi).
Dr Boulet holds a Bachelor’s Degree in Medical Biology from University of Quebec in Trois-Rivieres, a Master’s Degree in experimental medicine/immunology-immunochemistry as well as a PhD in physiology-endocrinology from Laval University in Quebec City. He also did a post-doctorate training at University of Pennsylvania (USA) in biochemistry-biophysics and a training program in Health Economics at York University (UK).
Viktoria Krasteva, CPA
Chief Financial Officer
Ms. Viktoria Krasteva brings to Devonian about 20 years of financial management and strategic leadership, with varied experience with financial capital markets across different industries including life sciences digital media and online services. She is a chartered professional accountant (CPA) and holds a bachelor’s degree in international commerce from the University of World Economy in Bulgaria and has graduate degrees in Public Accountancy from the universities of Concordia and McGill.
Vice-President, Research
Daniel Bouthillier has over 30 years of experience in research administration. He is presently Vice-President Research at Devonian Health Group Inc. Previously, he was a co-founder of Kaneq Pharma and Kaneq Bioscience. Mr. Bouthillier also occupied various positions at Merck&Co where he was Executive Director of Research Administration and Planning for various research sites in North America. He was also Executive Director for Merck Global Facilities Management with responsibilities for Canada, US, South America, and Asia. In previous positions, Mr. Bouthillier was Senior Scientist and Administrator at the Clinical Research Institute of Montreal and also Head of Biochemistry at l’Hôtel-Dieu de Sorel and at Fleury Hospital in Montreal. He sits on many evaluation committees and boards such as Centre québécois d’innovation en biotechnologie (CQIB), and Kanyr Pharma. Mr. Bouthillier received his Ph.D. in Clinical Sciences from the Université de Montréal and holds a certification in Clinical Biochemistry. He also completed an MBA at l’École des Hautes Études Commerciales in Montreal.
Nathalie Boucher, Ph.D.
Director, Research and Intellectual Property
Nathalie Boucher holds a bachelor’s degree in biochemistry, a master’s degree in biophysics, and a Ph.D. in environmental science (with a specialization in toxicology). She has many years of experience in both private and university research centers and stands out for her expertise in plant physiology, plant cell extraction, and enzyme stabilization. She has also contributed to the writing of numerous patents and scientific articles.